Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

There were also five new drugs referencing the ophthalmology drug Eylea (aflibercept) that gained FDA approval in 2024.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) came under pressure in the premarket on Tuesday after the company’s Q1 2025 financials fell short of Street forecasts amid disappointing sales from ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...

April 29 (Reuters) - Regeneron's (REGN.O), opens new tab first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking ...

(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) announced the presentation of 27 abstracts, including eight oral sessions, featuring EYLEA HD (aflibercept) Injection 8 mg at the upcoming ARVO ...

Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies ...

Yes, the erosion of EYLEA’s exclusivity and IP is concerning, and for good reason. However, the company’s financials, recent legal rulings, capital allocation and late-stage pipeline assets ...